The Motly Fool just came out with a nice article on this stock
The Motley Fool noted that Bionano Genomics’ non-sequencing-based optical mapping technology known as the Saphyr System was designed to rapidly characterize extremely long strands of genomic DNA. And the company recently acquired leading genomics data analysis software company BioDiscovery. This acquisition could be a “game-changing business development move for the company and its shareholders,” says The Motley Fool report.
It was a perfect time to cause a downtrend breakout and kick off a rally.
It's kind of messed up how publishers can manipulate stocks like this but such is the game.
Save half for a buy in on a dip to test the top of the trendline.
Targets $9 , $12 , ATH+
The Motley Fool noted that Bionano Genomics’ non-sequencing-based optical mapping technology known as the Saphyr System was designed to rapidly characterize extremely long strands of genomic DNA. And the company recently acquired leading genomics data analysis software company BioDiscovery. This acquisition could be a “game-changing business development move for the company and its shareholders,” says The Motley Fool report.
It was a perfect time to cause a downtrend breakout and kick off a rally.
It's kind of messed up how publishers can manipulate stocks like this but such is the game.
Save half for a buy in on a dip to test the top of the trendline.
Targets $9 , $12 , ATH+